Point72 Asset Management L.P. Purchases 225,508 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Point72 Asset Management L.P. grew its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 57.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 621,383 shares of the company's stock after purchasing an additional 225,508 shares during the quarter. Point72 Asset Management L.P. owned about 1.18% of Janux Therapeutics worth $33,269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in JANX. RA Capital Management L.P. boosted its holdings in shares of Janux Therapeutics by 13.1% during the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock worth $554,977,000 after buying an additional 1,200,000 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in shares of Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after buying an additional 1,115,412 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Janux Therapeutics by 41.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after buying an additional 1,038,996 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after buying an additional 986,750 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock worth $59,429,000 after buying an additional 950,557 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The stock was bought at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,001 shares of company stock valued at $313,964. 29.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on JANX shares. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Scotiabank dropped their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Finally, Wedbush reaffirmed an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded up $0.10 on Thursday, hitting $24.87. The company had a trading volume of 576,846 shares, compared to its average volume of 867,690. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -21.21 and a beta of 3.24. The stock has a 50 day moving average of $28.27 and a 200-day moving average of $40.12. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.